enGene (NASDAQ:ENGN – Get Free Report) posted its earnings results on Monday. The company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.91, FiscalAI reports. During the same quarter in the previous year, the business earned $0.51 earnings per share.
enGene Trading Up 9.4%
Shares of ENGN stock opened at $1.77 on Monday. enGene has a twelve month low of $1.40 and a twelve month high of $12.25. The stock has a market cap of $118.71 million, a price-to-earnings ratio of -0.79 and a beta of -0.29. The company’s 50-day moving average price is $4.41 and its 200-day moving average price is $7.24. The company has a current ratio of 11.75, a quick ratio of 11.75 and a debt-to-equity ratio of 0.09.
Analyst Upgrades and Downgrades
Several equities research analysts have recently issued reports on ENGN shares. Morgan Stanley downgraded shares of enGene from an “overweight” rating to an “equal weight” rating in a research note on Friday, May 8th. Leerink Partners lowered enGene from an “outperform” rating to a “market perform” rating and set a $2.00 target price for the company. in a research report on Friday, May 8th. Wells Fargo & Company reissued an “equal weight” rating and set a $2.00 price objective (down from $25.00) on shares of enGene in a report on Friday, May 8th. Weiss Ratings downgraded enGene from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 15th. Finally, Piper Sandler cut shares of enGene from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $7.00 to $4.00 in a report on Friday, May 8th. Four analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $12.68.
Institutional Trading of enGene
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Siren L.L.C. acquired a new position in enGene in the 4th quarter valued at about $30,126,000. Janus Henderson Group PLC purchased a new stake in enGene during the 4th quarter worth approximately $17,110,000. Millennium Management LLC lifted its holdings in enGene by 7,214.0% during the 4th quarter. Millennium Management LLC now owns 1,499,520 shares of the company’s stock worth $13,541,000 after buying an additional 1,479,018 shares in the last quarter. MPM Bioimpact LLC boosted its position in enGene by 247.1% in the 4th quarter. MPM Bioimpact LLC now owns 1,840,898 shares of the company’s stock valued at $16,623,000 after buying an additional 1,310,599 shares during the period. Finally, Polar Capital Holdings Plc acquired a new position in shares of enGene in the fourth quarter worth $10,321,000. Hedge funds and other institutional investors own 64.16% of the company’s stock.
About enGene
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Recommended Stories
- Five stocks we like better than enGene
- Mission Control: Floating In SpaceX’s Record-Breaking Orbit
- Forget AI for a Moment, This Homebuilder Is Stealing the Show
- Qualcomm Drops 25%, But Investor Day Could Reverse the Slide
- Meta to Follow Alphabet’s Footsteps? What an Equity Raise Could Mean
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.
